Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 13/20 | 0.64 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813131 | 1.00 | BCHE (0.64) | BCHENOX1MEN1MAPTALOX12 | |
| SCHEMBL30858752 | 0.91 | BCHE (0.54) | BCHEMEN1MAPTALOX12KMT2A | |
| SCHEMBL30858755 | 0.91 | BCHE (0.54) | BCHEMEN1MAPTALOX12KMT2A | |
| SCHEMBL12273366 | 0.86 | BCHE (0.49) | BCHENOX1MEN1MAPTALOX12 | |
| SCHEMBL2591986 | 0.84 | BCHE (0.47) | BCHENOX1MEN1MAPTALOX12 | |
| SCHEMBL15908923 | 0.83 | BCHE (0.46) | BCHENOX1SMN1; SMN2SLC6A3CDK1 | |
| SCHEMBL14058478 | 0.82 | BCHE (0.64) | BCHENOX1MEN1MAPTALOX12 | |
| SCHEMBL12273405 | 0.81 | BCHE (0.44) | BCHENOX1MEN1KMT2ATDP1 | |
| SCHEMBL10083549 | 0.80 | BCHE (0.61) | BCHEMEN1KMT2ATDP1 | |
| SCHEMBL14142982 | 0.80 | BCHE (0.61) | BCHENOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651874-A2 | PHENOTHIAZINYL COMPOUNDS AND USES | Prosetta Biosciences, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20240300940-A1 | Phenothiazinyl Compounds and Uses | PROSETTA BIOSCIENCES, INC., | 2024-09-12 | — | — | US | disclosed |
| WO-2024178120-A2 | PHENOTHIAZINYL COMPOUNDS AND USES | PROSETTA BIOSCIENCES, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300940-A1 | Phenothiazinyl Compounds and Uses | PSEN1, ACE, APP | BCHE 21/4885NOX1 577/4885MEN1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.